Literature DB >> 20886248

Active Paget's disease of bone with normal biomarkers of bone metabolism: a case report and review of the literature.

Lamprini Gkouva1, Maria Andrikoula, Vasilis Kontogeorgakos, Dionysios J Papachristou, Agathocles Tsatsoulis.   

Abstract

Paget's disease of bone is a focal skeletal disorder characterized by the formation of structurally abnormal bone, skeletal deformities, and other complications leading to bone pain and significant disability. It can involve one or more areas in a single bone (monostotic) or multiple bones (polyostotic). Most of the time the disease is asymptomatic and the diagnosis is made incidentally by increased levels of bone metabolism markers, especially alkaline phosphatase and is confirmed by specific findings in radiographs and radionuclide bone scan. In this report, we describe the case of a 65-year-old female with clinical and radiological findings of active Paget's disease of bone, but with absence of abnormal biochemical markers. The patient was given a dose of 5 mg zoledronic acid intravenously with significant clinical improvement within the next 6 months. The present case not only shows that Paget's disease of bone can occur in the setting of normal markers of bone metabolism but also that, in such cases, the response to treatment can be monitored by improvement in the clinical picture or by correct evaluation of the imaging findings.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20886248     DOI: 10.1007/s10067-010-1579-z

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  29 in total

1.  Paget's disease of bone: past and present.

Authors:  R Smith
Journal:  Bone       Date:  1999-05       Impact factor: 4.398

2.  Single infusion of zoledronate in Paget's disease of bone: a placebo-controlled, dose-ranging study.

Authors:  H Buckler; W Fraser; D Hosking; W Ryan; M J Maricic; F Singer; M Davie; I Fogelman; C A Birbara; A M Moses; K Lyles; P Selby; P Richardson; J Seaman; K Zelenakas; E Siris
Journal:  Bone       Date:  1999-05       Impact factor: 4.398

Review 3.  From the archives of the AFIP. Radiologic spectrum of Paget disease of bone and its complications with pathologic correlation.

Authors:  Stacy E Smith; Mark D Murphey; Kambiz Motamedi; Michael E Mulligan; Charles S Resnik; Francis H Gannon
Journal:  Radiographics       Date:  2002 Sep-Oct       Impact factor: 5.333

4.  On a Form of Chronic Inflammation of Bones (Osteitis Deformans).

Authors:  J Paget
Journal:  Med Chir Trans       Date:  1877

5.  Clinical delineation and localization to chromosome 9p13.3-p12 of a unique dominant disorder in four families: hereditary inclusion body myopathy, Paget disease of bone, and frontotemporal dementia.

Authors:  M J Kovach; B Waggoner; S M Leal; D Gelber; R Khardori; M A Levenstien; C A Shanks; G Gregg; M T Al-Lozi; T Miller; W Rakowicz; G Lopate; J Florence; G Glosser; Z Simmons; J C Morris; M P Whyte; A Pestronk; V E Kimonis
Journal:  Mol Genet Metab       Date:  2001-12       Impact factor: 4.797

6.  Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.

Authors:  David Hosking; Kenneth Lyles; Jacques P Brown; William D Fraser; Paul Miller; Manuel Diaz Curiel; Jean-Pierre Devogelaer; Michael Hooper; Guoqin Su; Ken Zelenakas; Judy Pak; Taiwo Fashola; Youssef Saidi; Erik Fink Eriksen; Ian R Reid
Journal:  J Bone Miner Res       Date:  2007-01       Impact factor: 6.741

7.  A negative search for a paramyxoviral etiology of Paget's disease of bone: molecular, immunological, and ultrastructural studies in UK patients.

Authors:  M H Helfrich; R P Hobson; P S Grabowski; A Zurbriggen; S L Cosby; G R Dickson; W D Fraser; C G Ooi; P L Selby; A J Crisp; R G Wallace; S Kahn; S H Ralston
Journal:  J Bone Miner Res       Date:  2000-12       Impact factor: 6.741

8.  Incidence and natural history of Paget's disease of bone in England and Wales.

Authors:  T P van Staa; P Selby; H G M Leufkens; K Lyles; J M Sprafka; C Cooper
Journal:  J Bone Miner Res       Date:  2002-03       Impact factor: 6.741

9.  Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).

Authors:  Leo Widler; Knut A Jaeggi; Markus Glatt; Klaus Müller; Rolf Bachmann; Michael Bisping; Anne-Ruth Born; Reto Cortesi; Gabriela Guiglia; Heidi Jeker; Rémy Klein; Ueli Ramseier; Johann Schmid; Gerard Schreiber; Yves Seltenmeyer; Jonathan R Green
Journal:  J Med Chem       Date:  2002-08-15       Impact factor: 7.446

10.  Use of zoledronic acid in the treatment of Paget's disease.

Authors:  Margaret Seton; Stephen M Krane
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

View more
  1 in total

Review 1.  Advances in Sensing Technologies for Monitoring of Bone Health.

Authors:  Seema Rani; Sanchita Bandyopadhyay-Ghosh; Subrata Bandhu Ghosh; Guozhen Liu
Journal:  Biosensors (Basel)       Date:  2020-04-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.